News and Trends 20 Dec 2016
UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data
UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […]